OncoCyte (NYSEMKT:OCX) has entered into definitive agreements with Pura Vida Investments, LLC, to purchase approx. $7.6M of its common shares in a registered offering.
The Company will sell an aggregate of 3,523,776 common shares at $2.156 per share.
Closing date is expected during the week of January 6.
The proceeds will be used for commercial launch of Company's lung cancer treatment stratification test, development of DetermaVu, acquire businesses or technologies and general corporate and working capital purposes
source SEEKING ALPHA
OncoCyte Corp. is a pharmaceutical company. It is focused on the discovery, development and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company was founded in September 2009 and is headquartered in Alameda, CA.
The Company will sell an aggregate of 3,523,776 common shares at $2.156 per share.
Closing date is expected during the week of January 6.
The proceeds will be used for commercial launch of Company's lung cancer treatment stratification test, development of DetermaVu, acquire businesses or technologies and general corporate and working capital purposes
source SEEKING ALPHA
OncoCyte Corp. is a pharmaceutical company. It is focused on the discovery, development and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company was founded in September 2009 and is headquartered in Alameda, CA.
⭐⭐⭐ Sign Up for Free ⭐⭐⭐
1) Download our Mobile App >>
Android: dexwirenews.com/APP
Apple: dexwirenews.com/iOS
2) Join our Telegram >> t.me/DEXWireNews
3) Follow @DEXWireNews on Social Media
1) Download our Mobile App >>
Android: dexwirenews.com/APP
Apple: dexwirenews.com/iOS
2) Join our Telegram >> t.me/DEXWireNews
3) Follow @DEXWireNews on Social Media